©2024 Stanford Medicine
Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
Not Recruiting
Trial ID: NCT00466713
Purpose
This study will investigate the effects of rosiglitazone, a medicine commonly used to treat
type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure
which is not due to heart attacks. The primary purpose of the study is to determine whether
treatment with an insulin-sensitizing medication will improve the heart's ability to
metabolize glucose (sugar).
Official Title
Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
Eligibility
Inclusion Criteria:
- Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive
heart failure
- History of Stage C-D heart failure with EF ≤ 40% during the course of the disease
- Treatment with a stable comprehensive heart failure regimen for at least 3 months
(including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless
intolerant)
- Age > 18 yrs
Exclusion Criteria:
- Cardiomyopathy due to one of the following:
- Ischemic heart disease
- Primary valvular lesion
- Hypertrophic cardiomyopathy
- Cardiac resynchronization within the last 3 months
- Transaminase values > 2.5 x upper limit of normal or history of liver disease
- Diagnosis of diabetes mellitus by:
- Diabetes previously diagnosed per patient history
- 2 or more fasting glucose values > 125 mg/dl
- Current NYHA class III or IV heart failure
- Serum creatinine > 1.6 mg/dl
- History of heart transplantation
- Pregnancy or active breast feeding
- Hospitalization for decompensated heart failure within 30 days prior to enrollment.
Intervention(s):
drug: Rosiglitazone therapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael B Fowler, MB
650-723-7846